Humanized Immune-Checkpoint Mice

Cancer immunotherapy is one of the most promising research areas in the field of cancer therapy. Major pharmaceutical companies in the world have devoted great effort to develop cancer immunity-related treatment methods. Results from clinical trials showed that the treatment efficacy is very high. Thus, Science magazine ranked cancer immunotherapy to be first place among the top ten scientific breakthroughs in 2013.

Immune checkpoints are molecules in the immune system that either turn up (co-stimulatory molecules) or turn down (inhibitory molecules) immune signals. Tumors can use these checkpoints to protect themselves from immune system attacks, particularly by T cells. Checkpoint therapy can block inhibitory checkpoints or activate stimulatory molecules, restoring immune system function.  In recent years, immune checkpoint drugs have become an important novel cancer treatment.

Biocytogen prepared and validated a series of immune checkpoint humanized mice. These models provide powerful tools for in vivo efficacy evaluation of human immune checkpoint antibodies.

Key features of Biocytogen’s humanized immune checkpoint mice:

  • Pure C57BL/6 genetic background leads more consistent and reliable experimental results. Biocytogen’s humanized immune checkpoint mice are all developed on the C57BL/6 genetic background, which is most commonly used in oncology, physiology, immunology and genetics studies.
  • The humanized mice are carefully designed and generated to maintain biological functions and ensure more reliable drug validation. Biocytogen uses a wealth of experience in animal model development, particularly humanized mouse design experience, to fully consider all factors that may interfere with the expression of humanized proteins and to perform a detailed assessment and accurate design for each project, ensuring sufficient humanization and humanized protein expression and intact signal transduction. With the humanized mice developed, in vivo efficacy evaluation of humanized immune checkpoint antibodies or inhibitors is more reliable and dependable.

Single Humanized Immune-checkpoint Mice

Product Product No Background
B-hBTLA Mice B-CM-018 C57BL/6
B-hCD27 Mice B-EM-024 C57BL/6
B-hCD28 Mice B-CM-019 C57BL/6
B-hCD3e Mice B-EM-026 C57BL/6
B-hCD40 Mice B-CM-020 C57BL/6
B-hCD47 (C) Mice B-CM-022 BALB/c
B-hCD47 Mice B-CM-021 C57BL/6
B-hCTLA4 Mice B-CM-024 C57BL/6
B-hHAVCR2 (TIM3) Mice B-CM-032 C57BL/6
B-hLAG3 Mice B-CM-046 C57BL/6
B-hPD-1 Mice B-CM-001 C57BL/6
B-hPD-1 Mice Plus B-CM-034 C57BL/6
B-hPD-L1 (CD274) Mice B-CM-029 C57BL/6
B-hSIRPα Mice B-CM-030 C57BL/6
B-hTIGIT Mice B-CM-031 C57BL/6
B-hTNFR2 110032 C57BL/6
B-hTNFRSF18 (GITR) Mice B-CM-025 C57BL/6
B-hTNFRSF4 (OX40) Mice B-CM-027 C57BL/6
B-hTNFRSF9 (4-1BB) Mice B-EM-023 C57BL/6

Double Humanized Immune-checkpoint Mice

Product Product No Background
B-hCTLA4/h4-1BB Mice B-DM-024 C57BL/6
B-hCTLA4/hLAG3 Mice B-DM-014 C57BL/6
B-hCTLA4/hOX40 Mice B-DM-016 C57BL/6
B-hCTLA4/hTIM3 Mice B-DM-015 C57BL/6
B-hOX40/h4-1BB Mice B-DM-012 C57BL/6
B-hPD-1/PD-L1 Mice B-DM-007 C57BL/6
B-hPD-1/h4-1BB Mice B-DM-001 C57BL/6
B-hPD-1/hBTLA Mice B-DM-002 C57BL/6
B-hPD-1/hCD27 Mice B-DM-003 C57BL/6
B-hPD-1/hCD40 Mice B-DM-011 C57BL/6
B-hPD-1/hCTLA4 Mice B-DM-004 C57BL/6
B-hPD-1/hGITR Mice B-DM-013 C57BL/6
B-hPD-1/hLAG3 Mice B-DM-005 C57BL/6
B-hPD-1/hOX40 Mice B-DM-006 C57BL/6
B-hPD-1/hTIGIT Mice B-DM-008 C57BL/6
B-hPD-1/hTIM3 Mice B-DM-009 C57BL/6
B-hPD-L1/h4-1BB Mice B-DM-020 C57BL/6
B-hPD-L1/hCD27 Mice B-DM-022 C57BL/6
B-hPD-L1/hCD40 Mice B-DM-021 C57BL/6
B-hPD-L1/hCTLA4 Mice B-DM-023 C57BL/6
B-hPD-L1/hLAG3 Mice B-DM-018 C57BL/6
B-hPD-L1/hOX40 Mice B-DM-019 C57BL/6
B-hPD-L1/hTIGIT Mice B-DM-017 C57BL/6
B-hPD-L1/hTIM3 Mice B-DM-026 C57BL/6
B-hSIRPα/hCD47 Mice B-DM-010 C57BL/6

Triple Humanized Immune-checkpoint Mice

Product Product No Background
B-hPD-1/hPD-L1/hCTLA4 130571 C57BL/6
B-hPD-1/hPD-L1/hTIM3 130574 C57BL/6
B-hPD-1/hSIRPA/hCD47 Mice B-TM-002 C57BL/6
B-hPD-L1/hSIRPA/hCD47 Mice B-TM-001 C57BL/6
Back to top